Abstract Number: 469 • 2012 ACR/ARHP Annual Meeting
Intra Articular Injections in Patients with Rheumatoid Arthritis: Analyses From the Behandelstrategiën Study
Background/Purpose: Intra articular (IA) corticosteroid injections aim at amelioration of symptoms of local inflammation in rheumatoid arthritis (RA). Some patients also report a systemic effect.…Abstract Number: 389 • 2012 ACR/ARHP Annual Meeting
Oral Glucocorticoid Sparing Effects of Rituximab in Rheumatoid Arthritis Patients Who Have Switched from an Anti-TNF Therapy – an Administrative Claims Database Analysis
Background/Purpose: The current treatment paradigm in RA is to attempt to decrease concomitant use of oral glucocorticoids (OGC). This study examined the OGC-sparing effects of…Abstract Number: 367 • 2012 ACR/ARHP Annual Meeting
Improved Fatigue-Related Quality of Life in CAPRA-2, a 12 Week Study of 5-Mg Modified (Delayed) Release Prednisone in Rheumatoid Arthritis
Background/Purpose: Quality of life in rheumatoid arthritis (RA) patients can be improved by reducing the common symptom of fatigue caused by disease related factors such…Abstract Number: 2352 • 2012 ACR/ARHP Annual Meeting
Temporal Artery Biopsy Culture in Tridimensional Matrix. an in Vitro Model for Functional Studies in Giant-Cell Arteritis
Background/Purpose: GCA is the most frequent systemic vasculitis in Europe and North America. In spite of the initial response to glucocorticoid treatment more than 60%…Abstract Number: 228 • 2012 ACR/ARHP Annual Meeting
Simultaneous Initiating of Glucocorticoids and disease-Modifying Antirheumatic Drug Therapy in Polymyositis and Dermatomyositis Patients Results in the Opportunity to Taper Dosage of Glucocorticoids Early
Background/Purpose: Glucocorticoids are the cornerstone of therapy in patients with polymyositis (PM) and dermatomyositis (DM). However, side effects are common. Furthermore, glucocorticoids exhibits an…Abstract Number: 2169 • 2012 ACR/ARHP Annual Meeting
Short to Medium Term Safety of Glucocorticoid Therapy in Rheumatoid Arthritis: A Systematic Review and Dose-Response Analysis of Randomized Controlled Trials
Background/Purpose: Concerns regarding Adverse Effects (AEs) often dominate decisions on applying Glucocorticoid (GC) therapy. Evidence of AEs is mainly based on observational data without proper…Abstract Number: 50 • 2012 ACR/ARHP Annual Meeting
Human Chondrocyte Dedifferentiation Is Accompagnied by CD105 Endoglin Expression, ALK-1/Smad1/5 Phosphorylation and Leptin Production – Stimulation by Prednisolone and Aldosterone Through the Glucocorticoid Receptor
Background/Purpose: Leptin, mainly produced by the adipose tissue including fat neighboring the joint, is considered as pro-inflammatory in osteoarthritis (OA). Normal cartilage does not…Abstract Number: 2155 • 2012 ACR/ARHP Annual Meeting
The Annualized Progression of Radiologic Damage in Placebo Arms of Rheumatoid Arthritis Trials Is Much Lower Than the Mean Annual Progression Since Disease Onset
Background/Purpose : A previous meta-analysis by Graudal and Jürgens (Arthritis Rheum. 2010;62:2852–63) challenged the belief that biologics better protect rheumatoid arthritis (RA) from joint destruction…Abstract Number: 36 • 2012 ACR/ARHP Annual Meeting
Role of FK506 Binding Protein 5 in Osteoclast Differentiation
Background/Purpose: RA is a chronic, systemic inflammatory disease characterized by the destruction of bone in the joints. Moreover, it is well appreciated that systemic osteoporosis…Abstract Number: 2085 • 2012 ACR/ARHP Annual Meeting
T Cell-Mediated Murine Antigen-Induced Arthritis Is Resistant to Transgenic Disruption of Glucocorticoid Signaling in Osteoblasts and Osteocytes in Vivo
Background/Purpose: The role of endogenous glucocorticoids (GC) in, and their contribution to the susceptibility and severity of rheumatoid arthritis remains inconclusive. We previously demonstrated that…Abstract Number: 2077 • 2012 ACR/ARHP Annual Meeting
IL-6 Blockade Augments the Anti-Inflammatory Effect without Increasing the Side Effects of Steroids in Collagen-Induced Arthritis
Background/Purpose: Steroids are the main therapy for chronic inflammatory diseases. They are very effective, but induce many side effects, such as osteoporosis, making it important…Abstract Number: 2057 • 2012 ACR/ARHP Annual Meeting
Analysis of the Adherence to the Monitoring of Glucocorticoid Eye Toxicity and of the Prevalence of Cataracts and Glaucoma Among Patients with Systemic Lupus Erythematosus
Background/Purpose: Cataracts and glaucoma are among the main causes of impaired visual acuity and have a prevalence respectively of 9-17% and 1-2% among subjects older…Abstract Number: 1996 • 2012 ACR/ARHP Annual Meeting
Are Changes in Bone Mineral Density Different Between Groups of Early Rheumatoid Arthritis Patients Treated According to a Tight Control Strategy with or without Prednisone, If Osteoporosis Prophylaxis Is Applied?
Background/Purpose: To describe effects on bone mineral density (BMD) of treatment according to EULAR guidelines with a methotrexate-based tight control strategy including 10 mg prednisone…Abstract Number: 1972 • 2012 ACR/ARHP Annual Meeting
Assessment of Fracture Risk in Postmenopausal Women with Rheumatoid Arthritis
Background/Purpose: The aim of this study is to determine the risk of osteoporotic fracture in postmenopausal women with rheumatoid arthritis (RA) and to examine the…Abstract Number: 1978 • 2012 ACR/ARHP Annual Meeting
A Web-Based Intervention Aimed to Improve Bone Health Among Individuals On Chronic Glucocorticoids
Background/Purpose: Despite a significant associated fracture risk, previous population-based studies document low osteoporosis treatment rates for individuals treated with chronic glucocorticoids (GCs) at risk for…